Vivita Technologies develops biomaterials for regenerative medicine, intending to alleviate the scarcity of donor organs and tissues.
Vivita Technologies has raised $1.5M in total funding. The most recent round was Grant. The last funding was announced in September 2022.
Vivita Technologies's investors include National Heart, Lung and Blood Institute.
Vivita Technologies is headquartered in Woodland, United States.
Vivita Technologies develops biomaterials for regenerative medicine, intending to alleviate the scarcity of donor organs and tissues.
Vivita Technologies is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Vivita Technologies — Funding & Investors." VCBacked, September 13, 2022, https://www.vcbacked.co/company/vivita-technologies. Accessed August 14, 2026.
VCBacked. (2022). Vivita Technologies — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/vivita-technologies
{{cite web |title=Vivita Technologies — Funding & Investors |url=https://www.vcbacked.co/company/vivita-technologies |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated